|
Market Closed -
Nasdaq
21:00:00 01/09/2026 BST
|
5-day change | 1st Jan Change | ||
| 438.12 USD | +1.92% |
|
-0.93% | +33.85% |
| 09-01 | UK regulator suspends rare-disease drug Tavneos for new patients over unreliable data | RE |
| 09-01 | Vertex Names Jonathan Poole Finance Chief as Crinetics Buy Closes | DJ |
Company Valuation: Amgen Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 126,718 | 140,139 | 154,142 | 140,103 | 176,250 | 236,862 | - | - |
| Change | - | 10.59% | 9.99% | -9.11% | 25.8% | 34.39% | - | - |
| Enterprise Value (EV) 1 | 151,990 | 169,779 | 207,811 | 188,229 | 221,725 | 278,347 | 272,690 | 267,693 |
| Change | - | 11.7% | 22.4% | -9.42% | 17.8% | 25.54% | -2.03% | -1.83% |
| P/E | 21.9x | 21.7x | 23.1x | 34.5x | 23x | 27.7x | 24.8x | 23.9x |
| PBR | 18.7x | 38.3x | 24.7x | 23.8x | 20.4x | 20.9x | 17.1x | 13.8x |
| PEG | - | 1.2x | 7.36x | -0.9x | 0.3x | 2.5x | 2.1x | 6.45x |
| Capitalization / Revenue | 4.88x | 5.32x | 5.47x | 4.19x | 4.8x | 6.08x | 5.89x | 5.7x |
| EV / Revenue | 5.85x | 6.45x | 7.37x | 5.63x | 6.03x | 7.15x | 6.78x | 6.45x |
| EV / EBITDA | 9.61x | 10.5x | 11.9x | 9.13x | 10.4x | 12.7x | 12.3x | 12x |
| EV / EBIT | 12.2x | 13.3x | 15.5x | 12.5x | 13.7x | 16.4x | 15.4x | 14.6x |
| EV / FCF | 18.1x | 19.3x | 28.2x | 18.1x | 27.4x | 25x | 18.5x | 17.4x |
| FCF Yield | 5.51% | 5.17% | 3.54% | 5.52% | 3.65% | 3.99% | 5.4% | 5.75% |
| Dividend per Share 2 | 7.04 | 7.76 | 8.52 | 9 | 9.52 | 10.09 | 10.66 | 11.12 |
| Rate of return | 3.13% | 2.95% | 2.96% | 3.45% | 2.91% | 2.3% | 2.43% | 2.54% |
| EPS 2 | 10.28 | 12.11 | 12.49 | 7.56 | 14.23 | 15.81 | 17.68 | 18.33 |
| Distribution rate | 68.5% | 64.1% | 68.2% | 119% | 66.9% | 63.8% | 60.3% | 60.7% |
| Net sales 1 | 25,979 | 26,323 | 28,190 | 33,424 | 36,751 | 38,939 | 40,196 | 41,525 |
| EBITDA 1 | 15,822 | 16,178 | 17,470 | 20,620 | 21,370 | 21,919 | 22,189 | 22,265 |
| EBIT 1 | 12,424 | 12,761 | 13,399 | 15,028 | 16,203 | 16,964 | 17,660 | 18,321 |
| Net income 1 | 5,893 | 6,552 | 6,717 | 4,090 | 7,711 | 8,598 | 9,394 | 9,890 |
| Net Debt 1 | 25,272 | 29,640 | 53,669 | 48,126 | 45,475 | 41,486 | 35,828 | 30,831 |
| Reference price 2 | 224.97 | 262.64 | 288.02 | 260.64 | 327.31 | 438.12 | 438.12 | 438.12 |
| Nbr of stocks (in thousands) | 563,266 | 533,579 | 535,178 | 537,533 | 538,481 | 540,632 | - | - |
| Announcement Date | 07/02/22 | 31/01/23 | 06/02/24 | 04/02/25 | 03/02/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 27.71x | 7.15x | 12.7x | 2.3% | 237B | |
| 33.02x | 11.99x | 24.3x | 0.6% | 1,034B | |
| 29.7x | - | - | 1.98% | 654B | |
| 33.18x | 7.69x | 15.99x | 2.64% | 459B | |
| 19.36x | 4.61x | 11.42x | 2.88% | 343B | |
| 22.91x | 5.89x | 14.6x | 2.71% | 307B | |
| 20.82x | 4.27x | 12.21x | 2.06% | 251B | |
| 13.18x | 4.74x | 9.88x | 3.82% | 202B | |
| -45.81x | 6.6x | 25.78x | 2.2% | 186B | |
| 17.89x | 3.38x | 8.62x | 6.03% | 163B | |
| Average | 17.20x | 6.26x | 15.06x | 2.72% | 383.43B | |
| Weighted average by Cap. | 23.81x | 7.80x | 17.33x | 2.13% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- AMGN Stock
- Valuation Amgen Inc.
Select your edition
All financial news and data tailored to specific country editions
